Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Yumanity Therapeutics, Inc. (YMTX : NSDQ)

• Company Description    Yumanity Therapeutics Inc. is a clinical-stage biopharmaceutical company involved in the treatment of neurodegenerative diseases. The company's product candidate includes YTX-7739.Yumanity Therapeutics Inc., formerly known as Proteostasis Therapeutics Inc., is based in BOSTON. Number of Employees: 41

• Price / Volume Information    Yesterday's Closing Price: $1.11 Daily Weekly Monthly 20 Day Moving Average: 48,220 shares Shares Outstanding: 10.84 (millions) Market Capitalization: $12.04 (millions) Beta: 0.88 52 Week High: $16.89 52 Week Low: $0.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.72% 2.13% 12 Week -14.61% -4.04% Year To Date -62.50% -54.19%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 40 GUEST STREET SUITE 4410 - BOSTON,MA 02135 USA ph: 617-409-5300 fax: - lroth@burnsmc.com http://www.yumanity.com

• General Corporate Information    Officers Richard Peters - Chief Executive Officer and President Michael D. Wyzga - Senior Vice President and Chief Financial Officer Marie Epstein - Vice President Patricia L. Allen - Director David Arkowitz - Director Peer Information Yumanity Therapeutics, Inc. (CORR.) Yumanity Therapeutics, Inc. (RSPI) Yumanity Therapeutics, Inc. (CGXP) Yumanity Therapeutics, Inc. (BGEN) Yumanity Therapeutics, Inc. (GTBP) Yumanity Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98872L102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 10.84 Most Recent Split Date: 12.00 (0.05:1) Beta: 0.88 Market Capitalization: $12.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.06 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.42 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.03 Price/Cash Flow: - Price / Sales: 2.17 EPS Growth vs. Year Ago Period: -45.88% vs. Previous Quarter: -24.00% Sales Growth vs. Year Ago Period: -71.04% vs. Previous Quarter: 34.25% ROE 03/31/22 - -162.54 12/31/21 - -108.22 09/30/21 - -147.18 ROA 03/31/22 - -72.00 12/31/21 - -51.59 09/30/21 - -73.43 Current Ratio 03/31/22 - 1.90 12/31/21 - 1.88 09/30/21 - 2.70 Quick Ratio 03/31/22 - 1.90 12/31/21 - 1.88 09/30/21 - 2.70 Operating Margin 03/31/22 - -798.73 12/31/21 - -491.15 09/30/21 - -605.00 Net Margin 03/31/22 - -798.73 12/31/21 - -491.15 09/30/21 - -605.00 Pre-Tax Margin 03/31/22 - -798.73 12/31/21 - -491.09 09/30/21 - -605.00 Book Value 03/31/22 - 1.08 12/31/21 - 2.28 09/30/21 - 3.15 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.31 09/30/21 - 0.27 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 23.84 09/30/21 - 21.23

Powered by Zacks Investment Research ©